<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Candidemia and invasive candidiasis in children: Management</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Candidemia and invasive candidiasis in children: Management</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Candidemia and invasive candidiasis in children: Management</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Judith R Campbell, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Debra L Palazzi, MD, MEd</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Morven S Edwards, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Diane Blake, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Sep 05, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>The term candidemia describes the presence of <em>Candida</em> species in the blood. <em>Candida</em> in a blood culture should prompt a search for the source; it should never be viewed as a contaminant. Invasive candidiasis encompasses both candidemia and deep-seated (ie, visceral) candidiasis (which may occur with or without candidemia) [<a href="#rid1">1</a>].</p><p>The management of candidemia and invasive candidiasis in children will be discussed here. An overview of candidal infections and the clinical manifestations and diagnosis of candidemia and invasive candidiasis in children, candidal infections in neonates, and candidal infections in adults are discussed separately:</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/5972.html" rel="external">"Candida infections in children"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/5976.html" rel="external">"Candidemia and invasive candidiasis in children: Clinical manifestations and diagnosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/5028.html" rel="external">"Epidemiology and risk factors for Candida infection in neonates"</a> and  <a class="medical medical_review" href="/z/d/html/5024.html" rel="external">"Clinical manifestations and diagnosis of Candida infection in neonates"</a> and  <a class="medical medical_review" href="/z/d/html/5029.html" rel="external">"Treatment of Candida infection in neonates"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/2442.html" rel="external">"Candidemia in adults: Epidemiology, microbiology, and pathogenesis"</a> and  <a class="medical medical_review" href="/z/d/html/2462.html" rel="external">"Clinical manifestations and diagnosis of candidemia and invasive candidiasis in adults"</a> and  <a class="medical medical_review" href="/z/d/html/2430.html" rel="external">"Management of candidemia and invasive candidiasis in adults"</a>.)</p><p></p><p class="headingAnchor" id="H2519417445"><span class="h1">DOCUMENTED INVASIVE CANDIDIASIS</span><span class="headingEndMark"> — </span>Treatment of documented candidemia and invasive candidiasis requires treatment with an antifungal agent and adequate source control.</p><p class="headingAnchor" id="H11"><span class="h2">Choice of antifungal therapy</span><span class="headingEndMark"> — </span>Antifungal therapy should be initiated as soon as possible after <em>Candida</em> is identified in a blood culture or other appropriate laboratory specimens (eg, urine culture, biopsy specimen culture). Early initiation of antifungal therapy (ie, within 24 hours of obtaining blood cultures) is associated with enhanced survival in adult patients with invasive candidiasis [<a href="#rid2">2-4</a>].</p><p>The choice of antifungal agent is guided by clinical features (eg, age, hemodynamic stability/severity of illness, site of infection, baseline kidney function) and the infecting <em>Candida</em> species (which affects susceptibility patterns) [<a href="#rid5">5,6</a>]. (See <a class="local">'Targeted therapy'</a> below.)</p><p>Our approach to antifungal therapy in children with invasive candidiasis is generally in keeping with the 2016 Infectious Diseases Society of America (IDSA) and 2012 European Society for Clinical Microbiology and Infectious Diseases (ESCMID) guidelines for the treatment of candidiasis (<a class="graphic graphic_table graphicRef109381" href="/z/d/graphic/109381.html" rel="external">table 1</a>) [<a href="#rid7">7,8</a>]. The treatment of candidiasis in neonates is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/5029.html" rel="external">"Treatment of Candida infection in neonates"</a>.)</p><p class="headingAnchor" id="H2519344657"><span class="h3">Pending speciation and susceptibility testing</span><span class="headingEndMark"> — </span>Pending speciation and results of susceptibility testing, the choice of therapy for <em>Candida</em> is influenced by whether the patient is colonized with resistant <em>Candida</em> species, if the patient has developed candidemia despite antifungal prophylaxis, and the proportion of candidemia isolates due to resistant species within a particular medical center. In addition, a positive germ tube test (if performed) suggests <em>Candida albicans </em>(<a class="graphic graphic_picture graphicRef67784" href="/z/d/graphic/67784.html" rel="external">picture 1</a>), which is generally susceptible to <a class="drug drug_pediatric" data-topicid="13303" href="/z/d/drug information/13303.html" rel="external">fluconazole</a>. When the <em>Candida</em> species and susceptibility are known, antifungal therapy can be adjusted as indicated. (See <a class="local">'Targeted therapy'</a> below.)</p><p>Some additional caveats for particular antifungal classes or agents (see <a class="local">'Antifungal agents'</a> below):</p><p class="bulletIndent1"><span class="glyph">●</span>Echinocandins (eg, <a class="drug drug_pediatric" data-topicid="12713" href="/z/d/drug information/12713.html" rel="external">micafungin</a>, <a class="drug drug_pediatric" data-topicid="12914" href="/z/d/drug information/12914.html" rel="external">caspofungin</a>, <a class="drug drug_pediatric" data-topicid="130086" href="/z/d/drug information/130086.html" rel="external">anidulafungin</a>) are not recommended for candidiasis of the eye, central nervous system (CNS), and urinary tract. They have poor penetration at these sites.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_pediatric" data-topicid="13303" href="/z/d/drug information/13303.html" rel="external">Fluconazole</a> should be avoided in children who are critically ill or are likely to have fluconazole-resistant isolates. Risk factors for fluconazole resistance include neutropenia and recent fluconazole use.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_pediatric" data-topicid="12885" href="/z/d/drug information/12885.html" rel="external">Voriconazole</a> is typically used as step-down therapy in patients with invasive infection due to <em>Candida krusei</em> and fluconazole-resistant, voriconazole-susceptible <em>Candida glabrata</em>.</p><p></p><p>Considering the caveats above, pending speciation and susceptibility testing, our suggestions for antifungal therapy for particular sites of infection are as follows (<a class="graphic graphic_table graphicRef109381" href="/z/d/graphic/109381.html" rel="external">table 1</a>) [<a href="#rid8">8</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Candidemia – An echinocandin or lipid formulation of amphotericin B are the primary therapies. Alternative agents include <a class="drug drug_pediatric" data-topicid="13303" href="/z/d/drug information/13303.html" rel="external">fluconazole</a> or <a class="drug drug_pediatric" data-topicid="12885" href="/z/d/drug information/12885.html" rel="external">voriconazole</a>.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Catheter-related thrombophlebitis – An echinocandin or lipid formulation of amphotericin B are the primary therapies. Removal or replacement of the central venous catheter (CVC) is discussed below. (See <a class="local">'Central venous catheter'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Endocarditis – Lipid formulation of amphotericin B or high-dose echinocandin are the primary therapies. Azole agents are an alternative, but data in children are limited. We add <a class="drug drug_pediatric" data-topicid="13304" href="/z/d/drug information/13304.html" rel="external">flucytosine</a> for children who receive lipid formulation of amphotericin B or who do not have a clinical response.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Intra-abdominal candidiasis – An echinocandin or lipid formulation of amphotericin B are the primary therapies. Alternative agents include <a class="drug drug_pediatric" data-topicid="13303" href="/z/d/drug information/13303.html" rel="external">fluconazole</a> or <a class="drug drug_pediatric" data-topicid="12885" href="/z/d/drug information/12885.html" rel="external">voriconazole</a>.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Hepatosplenic candidiasis – An echinocandin or lipid formulation of amphotericin B are the primary initial therapies. Initial therapy is followed by oral <a class="drug drug_pediatric" data-topicid="13303" href="/z/d/drug information/13303.html" rel="external">fluconazole</a> if fluconazole resistance is unlikely.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>CNS candidiasis – Lipid formulation of amphotericin B is the primary therapy We add <a class="drug drug_pediatric" data-topicid="13304" href="/z/d/drug information/13304.html" rel="external">flucytosine</a> for children who do not have a clinical response.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Ocular candidiasis – <a class="drug drug_pediatric" data-topicid="13303" href="/z/d/drug information/13303.html" rel="external">Fluconazole</a>, <a class="drug drug_pediatric" data-topicid="12885" href="/z/d/drug information/12885.html" rel="external">voriconazole</a>, or lipid formulation of amphotericin B are the primary therapies. We add <a class="drug drug_pediatric" data-topicid="13304" href="/z/d/drug information/13304.html" rel="external">flucytosine</a> for children who receive lipid formulation of amphotericin B and do not have a clinical response.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><em>Candida</em> pyelonephritis – Lipid formulation of amphotericin B or <a class="drug drug_pediatric" data-topicid="13303" href="/z/d/drug information/13303.html" rel="external">fluconazole</a> are the primary therapies. <a class="drug drug_pediatric" data-topicid="12885" href="/z/d/drug information/12885.html" rel="external">Voriconazole</a> is not recommended because the active form is minimally excreted in the urine.</p><p></p><p>Several large randomized trials in adults have shown that <a class="drug drug_pediatric" data-topicid="13303" href="/z/d/drug information/13303.html" rel="external">fluconazole</a> is as effective as <a class="drug drug_pediatric" data-topicid="12647" href="/z/d/drug information/12647.html" rel="external">amphotericin B deoxycholate</a> for the treatment of candidemia [<a href="#rid9">9-12</a>]. Similar comparative randomized trials in children have not been reported, but case reports and noncomparative trials of fluconazole in children suggest that it is safe, well tolerated, and effective [<a href="#rid13">13-15</a>].</p><p>Limited data from observational studies also suggest that echinocandins are safe and effective in children [<a href="#rid16">16-23</a>]. Use of echinocandins in children is supported by a multinational observational cohort study that compared echinocandin and azole or amphotericin B therapy in 540 children (&gt;120 days and &lt;18 years) with proven invasive candidiasis outside the CNS [<a href="#rid23">23</a>]. At 14 days, the crude risk of treatment failure was lower in the echinocandin than the azole/amphotericin B group (9.8 versus 13.1 percent); at 30 days, the crude risk of treatment failure was similar (11.1 versus 10.5 percent).</p><p class="headingAnchor" id="H275376940"><span class="h3">Targeted therapy</span><span class="headingEndMark"> — </span>Antifungal therapy can be adjusted as indicated when the susceptibility pattern is available and/or the species is identified. In hospitals where susceptibility testing is performed at an outside reference laboratory, prompt adjustment of antifungal therapy (eg, from an echinocandin to <a class="drug drug_pediatric" data-topicid="13303" href="/z/d/drug information/13303.html" rel="external">fluconazole</a>) may not be feasible.</p><p><em>C. albicans</em> is the most common cause of candidemia, but nonalbicans species are increasingly isolated. Among nonalbicans species, <em>C. glabrata</em> and <em>Candida parapsilosis</em> are most prominent, followed by <em>Candida tropicalis</em> and <em>C. krusei.</em> Antifungal susceptibility patterns and minimal inhibitory concentrations may vary according to species. (See  <a class="medical medical_review" href="/z/d/html/5976.html" rel="external">"Candidemia and invasive candidiasis in children: Clinical manifestations and diagnosis", section on 'Epidemiology'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong><em>C. albicans</em></strong><strong>, </strong><strong><em>C. parapsilosis</em></strong><strong>, and </strong><strong><em>C. tropicalis</em></strong> – <em>C. albicans</em>, <em>C. parapsilosis</em>, and <em>C. tropicalis</em> generally are susceptible to amphotericin B, azoles, and echinocandins, and initial therapy with any of these is reasonable for patients with invasive candidiasis that does not involve the eye, CNS, or urinary tract. Echinocandins are not recommended for candidiasis involving the eye, CNS, or urinary tract because they have relatively poor penetration at these sites. <a class="drug drug_pediatric" data-topicid="12885" href="/z/d/drug information/12885.html" rel="external">Voriconazole</a> is not recommended for candidiasis involving the urinary tract because the active form is minimally excreted in the urine.</p><p></p><p class="bulletIndent1">For patients with <em>C. albicans</em>, <em>C. parapsilosis</em>, or <em>C. tropicalis </em>isolates that are <a class="drug drug_pediatric" data-topicid="13303" href="/z/d/drug information/13303.html" rel="external">fluconazole</a> susceptible, we transition from initial antifungal therapy to fluconazole when they are clinically stable.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong><em>C. glabrata</em></strong> – For children with invasive candidiasis due to <em>C. glabrata</em>, we usually treat with amphotericin B. <a class="drug drug_pediatric" data-topicid="12885" href="/z/d/drug information/12885.html" rel="external">Voriconazole</a> may be an alternative for susceptible isolates from sites other than the urinary tract. Many <em>C. glabrata</em> species are resistant to <a class="drug drug_pediatric" data-topicid="13303" href="/z/d/drug information/13303.html" rel="external">fluconazole</a>. Although echinocandins are preferred for adult patients, some studies have shown increased rates of echinocandin resistance [<a href="#rid24">24-27</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong><em>C. krusei</em></strong> – For children with invasive candidiasis due to <em>C. krusei</em>, we usually treat with one of the following:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Amphotericin B – <em>C. krusei</em> may have decreased susceptibility to amphotericin B, requiring higher doses. (See <a class="local">'Amphotericin B'</a> below.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>An echinocandin, unless the infection involves the eye, CNS, or urinary tract (penetration at these sites is poor).</p><p></p><p class="bulletIndent1"><a class="drug drug_pediatric" data-topicid="12885" href="/z/d/drug information/12885.html" rel="external">Voriconazole</a> is an option if the isolate is susceptible and the infection does not involve the urinary tract. Resistance to voriconazole varies geographically. <em>C. krusei</em> is intrinsically resistant to <a class="drug drug_pediatric" data-topicid="13303" href="/z/d/drug information/13303.html" rel="external">fluconazole</a>.</p><p></p><p class="headingAnchor" id="H2532213260"><span class="h2">Source control</span></p><p class="headingAnchor" id="H3575216736"><span class="h3">Central venous catheter</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Children without neutropenia</strong> – In addition to prompt initiation of antifungal therapy, CVCs should be removed in nonneutropenic children with candidemia if the catheter is thought to be the source and it can be removed safely. CVCs often are the source of candidemia in patients without neutropenia [<a href="#rid28">28,29</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Children with neutropenia</strong> – Although we prefer to remove the CVC as soon as possible in children with neutropenia, the decision is individualized. Factors considered in this decision include the degree to which the child is dependent on central access (eg, for medications, parenteral nutrition), the anticipated difficulty of placing a central line, the possibility that the gastrointestinal tract in the source of invasive candidiasis, and the risk of removing or replacing the CVC.</p><p></p><p>When feasible, the CVC should be removed as soon as possible [<a href="#rid8">8,30</a>]. Fungemia clears more quickly when CVCs are removed [<a href="#rid31">31,32</a>], and in observational studies, retention of the CVC has been associated with increased mortality in children [<a href="#rid29">29,33,34</a>]. Although successful treatment without CVC removal has been described using antifungal lock therapy in addition to systemic antifungal therapy [<a href="#rid35">35-40</a>], additional studies are necessary before this approach can be routinely recommended.</p><p class="headingAnchor" id="H3886807033"><span class="h3">Other foci of infection</span><span class="headingEndMark"> — </span>Sources of infection other than a CVC are more common in neutropenic than nonneutropenic patients. Other foci of invasive candidiasis include abscesses or other fluid collections in the abdomen, chest, or bones. In addition to antifungal therapy, successful management of invasive candidiasis requires surgical or interventional radiology procedures to remove or drain these fluid collections [<a href="#rid4">4</a>].</p><p>Decisions regarding source control in children with candidal endocarditis or children with candidal pyelonephritis and a nephrostomy tube or stent should be made in consultation with an infectious diseases clinician and the child's cardiologist or nephrologist.</p><p class="headingAnchor" id="H237362476"><span class="h2">Monitoring response</span><span class="headingEndMark"> — </span>We obtain daily or every other day blood cultures after initiating treatment for candidemia to confirm the date of sterilization (which determines the duration of treatment). (See <a class="local">'Duration of antifungal therapy'</a> below.)</p><p>Children with invasive candidiasis without candidemia generally are monitored for resolution of signs and symptoms of infection as appropriate (eg, resolution of fever and characteristic lesions on abdominal imaging).</p><p class="headingAnchor" id="H2508085457"><span class="h2">Persistent candidemia</span><span class="headingEndMark"> — </span>If blood cultures remain positive for more than three days in a patient receiving appropriate antifungal therapy with adequate source control, then a search for a metastatic focus or endocarditis needs to be undertaken:</p><p class="bulletIndent1"><span class="glyph">●</span>Patients should be examined for thrombophlebitis or other focal evidence of infection (eg, focal muscle pain, abdominal pain). Signs and symptoms of infection guide the next steps in the evaluation, which often includes advanced imaging techniques (eg, ultrasonography, computed tomography, magnetic resonance imaging), especially in immunocompromised hosts.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>An echocardiogram generally is recommended because murmur may be absent in children with endocarditis. (See  <a class="medical medical_review" href="/z/d/html/5768.html" rel="external">"Infective endocarditis in children", section on 'Clinical manifestations'</a>.)</p><p></p><p>Patients with persistent candidemia who have a CVC in place should have the CVC removed. This is discussed in greater detail above. (See <a class="local">'Central venous catheter'</a> above.)</p><p class="headingAnchor" id="H1550496714"><span class="h2">Duration of antifungal therapy</span></p><p class="headingAnchor" id="H2235653712"><span class="h3">Suggested duration</span><span class="headingEndMark"> — </span>The appropriate duration of therapy for invasive candidiasis has not been studied. Our suggested durations are provided below (<a class="graphic graphic_table graphicRef109381" href="/z/d/graphic/109381.html" rel="external">table 1</a>):</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Candidemia</strong> – For children with candidemia without neutropenia who have no evidence of metastatic foci of infection, we generally treat for 14 days after the first negative blood culture and resolution of signs and symptoms. This is the duration that has been used in most clinical trials in adults [<a href="#rid9">9</a>] and is the recommended duration in the 2016 IDSA and 2012 ESCMID practice guidelines [<a href="#rid7">7,8</a>].</p><p></p><p class="bulletIndent1">For children with candidemia and neutropenia, we generally treat for 14 days after the first negative blood culture, resolution of signs and symptoms, and neutrophil count recovery.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>CVC-associated candidemia</strong> – For patients with CVC-associated candidemia, we generally treat for two weeks after catheter removal and candidemia has cleared.</p><p></p><p class="bulletIndent1">For patients with CVC-associated candidemia in which catheter retention is attempted, longer durations of therapy generally are needed.</p><p></p><p class="bulletIndent1">In such cases, performing an ultrasound of large veins to evaluate for thrombophlebitis may be prudent. Patients with <em>Candida</em> suppurative thrombophlebitis require catheter removal and incision and drainage or resection of the vein, if feasible. Antifungal treatment of <em>Candida</em> suppurative thrombophlebitis is generally continued for at least two weeks after candidemia has cleared and preferably when the thrombus has resolved. (See  <a class="medical medical_review" href="/z/d/html/2423.html" rel="external">"Candida endocarditis and suppurative thrombophlebitis", section on 'Suppurative thrombophlebitis'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Deep-seated invasive candidiasis</strong> – For children with deep-seated invasive candidiasis (eg, endocarditis or other metastatic focus of infection), longer durations of therapy are necessary and should be determined in consultation with an infectious diseases clinician.</p><p></p><p class="bulletIndent1">We typically treat endocarditis for a minimum of six weeks in patients with native value disease, but longer durations may be required in those with complications such as perivalvular abscesses [<a href="#rid41">41</a>]. For patients with prosthetic valve endocarditis caused by <em>Candida</em> species, chronic suppressive antifungal therapy usually is recommended to prevent recurrence. (See  <a class="medical medical_review" href="/z/d/html/2423.html" rel="external">"Candida endocarditis and suppurative thrombophlebitis", section on 'Chronic suppressive therapy'</a>.)</p><p></p><p class="headingAnchor" id="H1715923409"><span class="h3">Switching to oral therapy</span><span class="headingEndMark"> — </span>Data regarding when to switch to oral azole therapy in children are lacking. Switching to oral azole therapy may be reasonable in select patients without disseminated infection who are clinically stable, have azole-susceptible isolates and negative repeat blood cultures, and can tolerate oral medication.</p><p class="headingAnchor" id="H1402641259"><span class="h1">EMPIRIC ANTIFUNGAL THERAPY FOR AT-RISK PATIENTS</span><span class="headingEndMark"> — </span>Empiric antifungal therapy describes provision of antifungal therapy to patients at risk for invasive candidiasis who do not have documented invasive candidiasis, but who may nonetheless have invasive candidiasis, given the low sensitivity of microbiologic tests for <em>Candida</em>. (See  <a class="medical medical_review" href="/z/d/html/5976.html" rel="external">"Candidemia and invasive candidiasis in children: Clinical manifestations and diagnosis", section on 'Microbiologic studies'</a>.)</p><p>Although empiric antifungal therapy may be life saving in children with false negative mycologic studies, unnecessary use of empiric antifungal therapy may promote antifungal-resistant <em>Candida</em> spp.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Patients with neutropenia</strong> – Empiric antifungal therapy may be given routinely to children with neutropenia and fever that have failed to respond to four to five days of antibiotics because they are at substantially increased risk for invasive candidiasis. This is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/6059.html" rel="external">"Management of children with non-chemotherapy-induced neutropenia and fever", section on 'Addition of antifungal therapy'</a> and  <a class="medical medical_review" href="/z/d/html/6051.html" rel="external">"Fever in children with chemotherapy-induced neutropenia", section on 'Addition of antifungal therapy'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Patients without neutropenia </strong>– The initiation of empiric antifungal therapy is based on the clinical assessment of the patient in addition to mycologic evidence of invasive candidiasis (eg, polymerase chain reaction [PCR] assay, beta-D-glucan or other antigen assays) and data regarding the patient's colonization status (ie, <em>Candida is</em>olated in cultures from nonsterile sites), if available.</p><p></p><p class="bulletIndent1">For hospitalized critically ill children without neutropenia who have fever or sepsis not explained by another cause, we initiate empiric antifungal therapy if there is persistent fever (ie, four or five days) and the child has risk factors for invasive candidiasis or known <em>Candida</em> colonization. Risk factors for invasive candidiasis in children include immune suppression, damage to the gastrointestinal mucosa, central venous catheter, broad-spectrum antibiotics, parenteral nutrition, kidney failure requiring hemodialysis, and mechanical ventilation. (See  <a class="medical medical_review" href="/z/d/html/5976.html" rel="external">"Candidemia and invasive candidiasis in children: Clinical manifestations and diagnosis", section on 'Risk factors'</a>.)</p><p></p><p class="bulletIndent1">When empiric antifungal therapy is warranted, we generally use lipid formulation of amphotericin B or an echinocandin. Echinocandins are not recommended for candidiasis involving the eye, central nervous system, or urinary tract because they have relatively poor penetration at these sites.</p><p></p><p class="bulletIndent1">In a 2016 meta-analysis of randomized trials in critically ill nonneutropenic patients (predominantly adults), empiric antifungal treatment reduced the risk of proven invasive fungal infection (35.2 versus 64.8 percent; risk ratio 0.57, 95% CI 0.39-0.83; 17 trials, 2024 participants); however, it had no effect on mortality (approximately 24 percent in both groups) [<a href="#rid42">42</a>].</p><p></p><p class="bulletIndent1">The duration of empiric antifungal therapy in patients without evidence supporting a fungal infection depends upon the clinical response to empiric therapy:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>No clinical response – Empiric antifungal therapy should be stopped after four to five days in patients who have no clinical response and lack supporting evidence for fungal infection (ie, negative cultures, negative PCR, negative beta-D-glucan or other antigen assays).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Clinical response – In patients who have a clinical response to therapy but have negative fungal studies (ie, cultures, PCR, beta-D-glucan, other antigen assays), data are lacking about the appropriate duration of antifungal therapy. However, most experts recommend a treatment course for presumptive candidemia (ie, a minimum of two weeks and resolution of signs and symptoms). We agree with this approach.</p><p></p><p class="headingAnchor" id="H327877656"><span class="h1">ANTIFUNGAL AGENTS</span><span class="headingEndMark"> — </span>Amphotericin B and <a class="drug drug_pediatric" data-topicid="13303" href="/z/d/drug information/13303.html" rel="external">fluconazole</a> have traditionally been used in the treatment of candidemia in children because of their long-standing safety and efficacy. However, lipid formulations of amphotericin B, other azoles, and echinocandins are increasingly used in children as information about their safety, efficacy, and pharmacokinetics becomes available [<a href="#rid43">43-46</a>].</p><p class="headingAnchor" id="H1828479465"><span class="h2">Amphotericin B</span></p><p class="headingAnchor" id="H2729557882"><span class="h3">Lipid formulation of amphotericin B</span><span class="headingEndMark"> — </span>Lipid amphotericin B preparations (eg, <a class="drug drug_pediatric" data-topicid="12669" href="/z/d/drug information/12669.html" rel="external">liposomal amphotericin B</a>, <a class="drug drug_pediatric" data-topicid="12660" href="/z/d/drug information/12660.html" rel="external">amphotericin B lipid complex</a>) are preferred for most children, particularly those who are receiving other nephrotoxic agents (eg, posttransplantation) and patients with decreased or decreasing glomerular filtration rate (GFR).</p><p class="bulletIndent1"><span class="glyph">●</span>The usual dose is 3 to 5 mg/kg IV once per day; 5 mg/kg per day may be warranted if <em>C. glabrata</em> or <em>C. krusei</em> is suspected or identified.</p><p></p><p>Although the incidence of decreased kidney function and infusion-related adverse events with lipid formulations of amphotericin B are lower than rates observed with <a class="drug drug_pediatric" data-topicid="12647" href="/z/d/drug information/12647.html" rel="external">amphotericin B deoxycholate</a>, these complications do occur. Therefore, during therapy with lipid formulations of amphotericin B, we closely monitor serum creatinine and electrolytes, including magnesium and potassium. Serum potassium should be ≥3 mmol/L (3 mEq/L) before administration of lipid formulations of amphotericin B. Daily laboratory monitoring may be required. An alternative antifungal agent (eg, echinocandin, azole) may be needed if there is a rise in serum creatinine or persistent derangement of serum electrolytes.</p><p>The pharmacokinetics of lipid formulations in children are similar to those in adults [<a href="#rid47">47</a>]. (See  <a class="medical medical_review" href="/z/d/html/476.html" rel="external">"Pharmacology of amphotericin B", section on 'Lipid-based amphotericin B formulations'</a>.)</p><p class="headingAnchor" id="H2040771150"><span class="h3">Amphotericin B deoxycholate</span><span class="headingEndMark"> — </span>Most of the experience with treating fungal infections in children has been with <a class="drug drug_pediatric" data-topicid="12647" href="/z/d/drug information/12647.html" rel="external">amphotericin B deoxycholate</a> (conventional amphotericin). However, use of amphotericin B deoxycholate beyond the neonatal period has fallen out of favor because of drug-associated toxicities.</p><p>Although very young children tend to tolerate <a class="drug drug_pediatric" data-topicid="12647" href="/z/d/drug information/12647.html" rel="external">amphotericin B deoxycholate</a> better than adults and have less nephrotoxicity, we use lipid amphotericin B for most children, particularly those with decreased or decreasing GFR and those receiving other nephrotoxic drugs. GFR can be estimated from height and serum creatinine (<a class="calc calc_professional" href="/z/d/html/13424.html" rel="external">calculator 1</a>) [<a href="#rid48">48</a>]. The threshold for choosing lipid amphotericin B is individualized according to the need for other nephrotoxic drugs and trends in GFR over time.</p><p class="bulletIndent1"><span class="glyph">●</span>The recommended dose of <a class="drug drug_pediatric" data-topicid="12647" href="/z/d/drug information/12647.html" rel="external">amphotericin B deoxycholate</a> for infants and children is 1 mg/kg intravenously (IV) per day.</p><p></p><p class="bulletIndent1">Doses as high as 1.5 mg/kg per day have been used for meningitis or disseminated infection with focal liver or kidney disease, but if higher doses are needed, changing to a lipid formulation may be warranted. (See <a class="local">'Lipid formulation of amphotericin B'</a> above.)</p><p></p><p>During therapy with <a class="drug drug_pediatric" data-topicid="12647" href="/z/d/drug information/12647.html" rel="external">amphotericin B deoxycholate</a>, we closely monitor serum creatinine and electrolytes, including magnesium and potassium. Serum potassium should be ≥3 mmol/L (3 mEq/L) before administration of amphotericin B. Daily laboratory monitoring may be required. Lipid formulations of amphotericin or an echinocandin should be used if there is a rise in serum creatinine [<a href="#rid43">43</a>]. (See  <a class="medical medical_review" href="/z/d/html/476.html" rel="external">"Pharmacology of amphotericin B"</a> and  <a class="medical medical_review" href="/z/d/html/2364.html" rel="external">"Amphotericin B nephrotoxicity"</a>.)</p><p class="headingAnchor" id="H2983639708"><span class="h2">Echinocandins</span><span class="headingEndMark"> — </span>Echinocandins include <a class="drug drug_pediatric" data-topicid="12914" href="/z/d/drug information/12914.html" rel="external">caspofungin</a>, <a class="drug drug_pediatric" data-topicid="130086" href="/z/d/drug information/130086.html" rel="external">anidulafungin</a>, and <a class="drug drug_pediatric" data-topicid="12713" href="/z/d/drug information/12713.html" rel="external">micafungin</a>. Echinocandins are an option for primary therapy for children with invasive candidiasis that does <strong>not</strong> involve they eye, central nervous system, or urinary tract (echinocandins have relatively poor penetration at these sites).</p><p>Echinocandins are first-line agents for the treatment of invasive candidiasis in adults, based upon randomized trials demonstrating that they are as safe and effective as amphotericin B or <a class="drug drug_pediatric" data-topicid="13303" href="/z/d/drug information/13303.html" rel="external">fluconazole</a> [<a href="#rid49">49-52</a>]. Although data in children are limited, echinocandins appear to be safe and effective [<a href="#rid16">16-23</a>].</p><p>General dosing guidelines for echinocandins in children are as provided below [<a href="#rid17">17,53-58</a>]. Before starting therapy, consultation with an infectious diseases pharmacist or clinician may be warranted.</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_pediatric" data-topicid="12914" href="/z/d/drug information/12914.html" rel="external">Caspofungin</a> – Caspofungin is available for the treatment of candidemia and invasive candidiasis in children ≥3 months of age. It is also available for empiric treatment of suspected fungal infection in children ≥3 months of age with fever and neutropenia. Caspofungin is dosed by body surface area (BSA) rather than weight. The BSA is calculated from the child's height and weight using a nomogram or calculator (<a class="calc calc_professional" href="/z/d/html/13406.html" rel="external">calculator 2</a>) [<a href="#rid17">17,18,59,60</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The recommended regimen is a single loading dose of 70 mg/m<sup>2</sup> per day (maximum dose 70 mg) IV, followed by 50 mg/m<sup>2</sup> per day (maximum dose 70 mg) IV.</p><p></p><p class="bulletIndent1">Patients receiving other medications that induce drug clearance (eg, <a class="drug drug_pediatric" data-topicid="12702" href="/z/d/drug information/12702.html" rel="external">phenytoin</a>, <a class="drug drug_pediatric" data-topicid="12767" href="/z/d/drug information/12767.html" rel="external">rifampin</a>) may require increased doses (within the maximum dose of 70 mg).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_pediatric" data-topicid="12713" href="/z/d/drug information/12713.html" rel="external">Micafungin</a></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients ≥4 months of age, <a class="drug drug_pediatric" data-topicid="12713" href="/z/d/drug information/12713.html" rel="external">micafungin</a> is available for the treatment of candidemia, acute disseminated candidiasis, <em>Candida</em> peritonitis and abscesses, esophageal candidiasis, and prophylaxis of <em>Candida</em> infections in patients undergoing hematopoietic cell transplantation [<a href="#rid61">61</a>].</p><p></p><p class="bulletIndent2">The suggested dose varies according to the indication and clinical response. For the treatment of candidemia and invasive candidiasis, the initial dose is 2 mg/kg IV once daily (maximum 100 mg per day). Increased doses (up to 10 mg/kg per day) may be necessary in children &lt;40 kg or those without an adequate clinical response to a lower dose [<a href="#rid8">8,62,63</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For infants &lt;4 months of age, <a class="drug drug_pediatric" data-topicid="12713" href="/z/d/drug information/12713.html" rel="external">micafungin</a> is available for the treatment of candidemia, acute disseminated candidiasis, and <em>Candida</em> peritonitis and abscesses, provided that the infants do not have meningoencephalitis and/or ocular dissemination [<a href="#rid61">61</a>]. </p><p></p><p class="bulletIndent2">The suggested dose is 4 mg/kg IV once daily [<a href="#rid61">61</a>]. Based on limited data, increased doses (up to 10 mg/kg per day) may be necessary for infants who do not respond to lower doses [<a href="#rid62">62,63</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_pediatric" data-topicid="130086" href="/z/d/drug information/130086.html" rel="external">Anidulafungin</a> – For patients ≥1 month of age, anidulafungin is available for the treatment of candidemia, intra-abdominal abscess, and peritonitis [<a href="#rid64">64</a>].</p><p></p><p class="bulletIndent1">The recommended regimen is a single loading dose of 3 mg/kg IV (maximum dose 200 mg) on day 1, followed by 1.5 mg/kg IV once daily (maximum dose 100 mg) for at least 14 days after the last positive culture [<a href="#rid64">64</a>].</p><p></p><p class="headingAnchor" id="H1313370116"><span class="h2">Azole antifungal agents</span><span class="headingEndMark"> — </span>Azole antifungal agents available for the treatment of candidemia and invasive candidiasis in children include <a class="drug drug_pediatric" data-topicid="13303" href="/z/d/drug information/13303.html" rel="external">fluconazole</a> and <a class="drug drug_pediatric" data-topicid="12885" href="/z/d/drug information/12885.html" rel="external">voriconazole</a>. The safety and efficacy of other azole antifungal agents (eg, <a class="drug drug_pediatric" data-topicid="12997" href="/z/d/drug information/12997.html" rel="external">posaconazole</a>, <a class="drug drug_pediatric" data-topicid="139000" href="/z/d/drug information/139000.html" rel="external">isavuconazole</a>) in the treatment of invasive candidiasis in children have not been adequately studied.</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_pediatric" data-topicid="13303" href="/z/d/drug information/13303.html" rel="external">Fluconazole</a> – Fluconazole is used more often than <a class="drug drug_pediatric" data-topicid="12885" href="/z/d/drug information/12885.html" rel="external">voriconazole</a> in the treatment of invasive candidiasis in children. Fluconazole should be avoided in children who are critically ill or are likely to have fluconazole-resistant isolates. Risk factors for fluconazole resistance include neutropenia and recent fluconazole use. Fluconazole should not be used if <em>C. krusei</em> is suspected or identified. <em>C. krusei</em> is intrinsically resistant to fluconazole [<a href="#rid65">65</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The recommended dose of <a class="drug drug_pediatric" data-topicid="13303" href="/z/d/drug information/13303.html" rel="external">fluconazole</a> for children is 12 mg/kg IV per day [<a href="#rid66">66</a>].</p><p></p><p class="bulletIndent1">Children require higher doses of <a class="drug drug_pediatric" data-topicid="13303" href="/z/d/drug information/13303.html" rel="external">fluconazole</a> than adults because the half-life is shorter in children [<a href="#rid66">66,67</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_pediatric" data-topicid="12885" href="/z/d/drug information/12885.html" rel="external">Voriconazole</a> – Voriconazole generally is used as step-down therapy in patients with invasive infection due to <em>C. krusei</em> and fluconazole-resistant, voriconazole-susceptible <em>C. glabrata</em>.</p><p></p><p class="bulletIndent1"><a class="drug drug_pediatric" data-topicid="12885" href="/z/d/drug information/12885.html" rel="external">Voriconazole</a> is not recommended for patients with urinary candidiasis because the active form is minimally excreted in the urine.</p><p></p><p class="bulletIndent1">The recommended dose of <a class="drug drug_pediatric" data-topicid="12885" href="/z/d/drug information/12885.html" rel="external">voriconazole</a> for children varies according to age [<a href="#rid68">68,69</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>&lt;12 years – 9 mg/kg IV twice daily as a loading dose for the first day and then 8 mg/kg every 12 hours</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>≥12 years – 6 mg/kg IV twice daily as a loading dose for the first day and then 4 mg/kg every 12 hours</p><p></p><p class="bulletIndent1">Younger children require higher doses of <a class="drug drug_pediatric" data-topicid="12885" href="/z/d/drug information/12885.html" rel="external">voriconazole</a> than older children and adults because of differing elimination patterns (linear elimination until approximately 12 years of age and nonlinear elimination thereafter) [<a href="#rid68">68</a>].</p><p></p><p class="bulletIndent1">We monitor serum <a class="drug drug_pediatric" data-topicid="12885" href="/z/d/drug information/12885.html" rel="external">voriconazole</a> concentrations and adjust the dose to maintain trough concentration between 1 and 5 mcg/mL [<a href="#rid70">70-72</a>]. Trough concentrations &gt;5 mcg/mL are associated with toxicity [<a href="#rid71">71,72</a>]. In observational studies, the pharmacokinetics of voriconazole have varied markedly from patient to patient [<a href="#rid73">73-76</a>]. In one study, voriconazole trough concentrations of &gt;1 mcg/mL were associated with increased survival from invasive fungal infection (9 of 46 children had invasive candidiasis) [<a href="#rid73">73</a>]. Pending prospective studies confirming these results, it is prudent to maintain a trough concentration of at least 1 mcg/mL.</p><p></p><p class="headingAnchor" id="H3593330490"><span class="h1">OUTCOME</span><span class="headingEndMark"> — </span>Untreated candidemia has a mortality rate of over 60 percent [<a href="#rid77">77</a>]. With treatment, the overall mortality of candidemia in children ranges from 9 to 40 percent [<a href="#rid78">78-80</a>].</p><p>Factors associated with increased mortality include [<a href="#rid2">2-4,78,81,82</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Delayed initiation or inadequate dosing of antifungal therapy</p><p class="bulletIndent1"><span class="glyph">●</span>Septic shock</p><p class="bulletIndent1"><span class="glyph">●</span>Inadequate source control (ie, failure to remove a central venous catheter or to drain or surgically remove a deep-seated source)</p><p class="bulletIndent1"><span class="glyph">●</span>Increased severity of illness (eg, as determined by a validated scoring system)</p><p class="bulletIndent1"><span class="glyph">●</span>Infection with an antifungal-resistant strain</p><p class="bulletIndent1"><span class="glyph">●</span>Immunosuppressive therapy</p><p class="bulletIndent1"><span class="glyph">●</span>The infecting <em>Candida</em> species (<em>C. albicans</em> and <em>C. glabrata</em> have increased mortality compared with <em>C. parapsilosis</em>)</p><p></p><p class="headingAnchor" id="H4053869140"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/104270.html" rel="external">"Society guideline links: Candidiasis"</a>.)</p><p class="headingAnchor" id="H275376660"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Introduction</strong> – The term candidemia describes the presence of <em>Candida</em> species in the blood. <em>Candida</em> in a blood culture should prompt a search for the source; it should never be viewed as a contaminant. (See <a class="local">'Introduction'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Treatment of documented invasive candidiasis</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Choice of antifungal therapy</strong> – Antifungal therapy should be initiated as soon as possible after <em>Candida</em> is identified in a blood culture. The choice of antifungal agent is guided by clinical features (age, hemodynamic stability/severity of illness, site of infection, baseline kidney function, neutropenia) and the infecting <em>Candida</em> species (<a class="graphic graphic_table graphicRef109381" href="/z/d/graphic/109381.html" rel="external">table 1</a>). (See <a class="local">'Choice of antifungal therapy'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Source control</strong></p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Children without neutropenia – We remove central venous catheters (CVCs) in nonneutropenic children with candidemia if the catheter is thought to be the source and it can be removed safely. (See <a class="local">'Source control'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Children with neutropenia – We prefer to remove the CVC as soon as possible in children with neutropenia. However, the decision is individualized. Factors considered in this decision include the degree to which the child is dependent on central access (eg, for medications, parenteral nutrition), the anticipated difficulty of placing a central line, the possibility that the gastrointestinal tract in the source of invasive candidiasis, and the risk of removing or replacing the CVC. (See <a class="local">'Source control'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Monitoring response</strong> – We obtain daily or every other day blood cultures after initiating treatment for invasive candidiasis to confirm the date of sterilization, which affects the duration of treatment. (See <a class="local">'Monitoring response'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Duration of therapy</strong> – For children with candidemia and no evidence of metastatic foci of infection, we generally treat for a minimum of two weeks after blood cultures become negative (<a class="graphic graphic_table graphicRef109381" href="/z/d/graphic/109381.html" rel="external">table 1</a>).</p><p></p><p class="bulletIndent2">For children with deep-seated invasive candidiasis (eg, endocarditis or other metastatic focus of infection), longer durations of therapy are necessary and should be determined in consultation with an infectious diseases clinician. (See <a class="local">'Duration of antifungal therapy'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Empiric antifungal therapy for at-risk patients</strong> – For hospitalized critically ill children without neutropenia who have fever or sepsis not explained by another cause, we initiate empiric antifungal therapy if there is persistent fever (ie, four or five days) and the child has risk factors for invasive candidiasis or known <em>Candida</em> colonization. Risk factors for invasive candidiasis in children include immune suppression, damage to the gastrointestinal mucosa, CVC, broad-spectrum antibiotics, parenteral nutrition, kidney failure requiring hemodialysis, and mechanical ventilation. (See <a class="local">'Empiric antifungal therapy for at-risk patients'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Outcome</strong> – Even with appropriate therapy, the mortality of candidemia ranges from 9 to 40 percent. Factors associated with increased mortality include delayed initiation or inadequate dosing of antifungal therapy, inadequate source control, increased severity of illness, and immunosuppressive therapy. (See <a class="local">'Outcome'</a> above.)</p><p></p><p class="headingAnchor" id="H1726014949"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The editorial staff at UpToDate would like to acknowledge Carol A Kauffman, MD, who contributed to an earlier version of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Clancy CJ, Nguyen MH. Finding the "missing 50%" of invasive candidiasis: how nonculture diagnostics will improve understanding of disease spectrum and transform patient care. Clin Infect Dis 2013; 56:1284.</a></li><li><a class="nounderline abstract_t">Garey KW, Rege M, Pai MP, et al. Time to initiation of fluconazole therapy impacts mortality in patients with candidemia: a multi-institutional study. Clin Infect Dis 2006; 43:25.</a></li><li><a class="nounderline abstract_t">Morrell M, Fraser VJ, Kollef MH. Delaying the empiric treatment of candida bloodstream infection until positive blood culture results are obtained: a potential risk factor for hospital mortality. Antimicrob Agents Chemother 2005; 49:3640.</a></li><li><a class="nounderline abstract_t">Kollef M, Micek S, Hampton N, et al. Septic shock attributed to Candida infection: importance of empiric therapy and source control. Clin Infect Dis 2012; 54:1739.</a></li><li><a class="nounderline abstract_t">Blyth CC, Palasanthiran P, O'Brien TA. Antifungal therapy in children with invasive fungal infections: a systematic review. Pediatrics 2007; 119:772.</a></li><li><a class="nounderline abstract_t">Steinbach WJ. Antifungal agents in children. Pediatr Clin North Am 2005; 52:895.</a></li><li><a class="nounderline abstract_t">Hope WW, Castagnola E, Groll AH, et al. ESCMID* guideline for the diagnosis and management of Candida diseases 2012: prevention and management of invasive infections in neonates and children caused by Candida spp. Clin Microbiol Infect 2012; 18 Suppl 7:38.</a></li><li><a class="nounderline abstract_t">Pappas PG, Kauffman CA, Andes DR, et al. Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America. Clin Infect Dis 2016; 62:e1.</a></li><li><a class="nounderline abstract_t">Rex JH, Bennett JE, Sugar AM, et al. A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. Candidemia Study Group and the National Institute. N Engl J Med 1994; 331:1325.</a></li><li><a class="nounderline abstract_t">Phillips P, Shafran S, Garber G, et al. Multicenter randomized trial of fluconazole versus amphotericin B for treatment of candidemia in non-neutropenic patients. Canadian Candidemia Study Group. Eur J Clin Microbiol Infect Dis 1997; 16:337.</a></li><li><a class="nounderline abstract_t">Abele-Horn M, Kopp A, Sternberg U, et al. A randomized study comparing fluconazole with amphotericin B/5-flucytosine for the treatment of systemic Candida infections in intensive care patients. Infection 1996; 24:426.</a></li><li><a class="nounderline abstract_t">Anaissie EJ, Darouiche RO, Abi-Said D, et al. Management of invasive candidal infections: results of a prospective, randomized, multicenter study of fluconazole versus amphotericin B and review of the literature. Clin Infect Dis 1996; 23:964.</a></li><li><a class="nounderline abstract_t">Kaufman D, Boyle R, Hazen KC, et al. Fluconazole prophylaxis against fungal colonization and infection in preterm infants. N Engl J Med 2001; 345:1660.</a></li><li><a class="nounderline abstract_t">Presterl E, Graninger W. Efficacy and safety of fluconazole in the treatment of systemic fungal infections in pediatric patients. Multicentre Study Group. Eur J Clin Microbiol Infect Dis 1994; 13:347.</a></li><li><a class="nounderline abstract_t">Schwarze R, Penk A, Pittrow L. Treatment of candidal infections with fluconazole in neonates and infants. Eur J Med Res 2000; 5:203.</a></li><li><a class="nounderline abstract_t">Zaoutis T, Lehrnbecher T, Groll AH, et al. Safety experience with caspofungin in pediatric patients. Pediatr Infect Dis J 2009; 28:1132.</a></li><li><a class="nounderline abstract_t">Benjamin DK Jr, Driscoll T, Seibel NL, et al. Safety and pharmacokinetics of intravenous anidulafungin in children with neutropenia at high risk for invasive fungal infections. Antimicrob Agents Chemother 2006; 50:632.</a></li><li><a class="nounderline abstract_t">Zaoutis TE, Jafri HS, Huang LM, et al. A prospective, multicenter study of caspofungin for the treatment of documented Candida or Aspergillus infections in pediatric patients. Pediatrics 2009; 123:877.</a></li><li><a class="nounderline abstract_t">Maertens JA, Madero L, Reilly AF, et al. A randomized, double-blind, multicenter study of caspofungin versus liposomal amphotericin B for empiric antifungal therapy in pediatric patients with persistent fever and neutropenia. Pediatr Infect Dis J 2010; 29:415.</a></li><li><a class="nounderline abstract_t">Arrieta AC, Maddison P, Groll AH. Safety of micafungin in pediatric clinical trials. Pediatr Infect Dis J 2011; 30:e97.</a></li><li><a class="nounderline abstract_t">Manzoni P, Wu C, Tweddle L, Roilides E. Micafungin in premature and non-premature infants: a systematic review of 9 clinical trials. Pediatr Infect Dis J 2014; 33:e291.</a></li><li><a class="nounderline abstract_t">Roilides E, Carlesse F, Tawadrous M, et al. Safety, Efficacy and Pharmacokinetics of Anidulafungin in Patients 1 Month to &lt;2 Years of Age With Invasive Candidiasis, Including Candidemia. Pediatr Infect Dis J 2020; 39:305.</a></li><li><a class="nounderline abstract_t">Fisher BT, Zaoutis TE, Xiao R, et al. Comparative Effectiveness of Echinocandins vs Triazoles or Amphotericin B Formulations as Initial Directed Therapy for Invasive Candidiasis in Children and Adolescents. J Pediatric Infect Dis Soc 2021.</a></li><li><a class="nounderline abstract_t">Pfaller MA, Castanheira M, Lockhart SR, et al. Frequency of decreased susceptibility and resistance to echinocandins among fluconazole-resistant bloodstream isolates of Candida glabrata. J Clin Microbiol 2012; 50:1199.</a></li><li><a class="nounderline abstract_t">Thompson GR 3rd, Wiederhold NP, Vallor AC, et al. Development of caspofungin resistance following prolonged therapy for invasive candidiasis secondary to Candida glabrata infection. Antimicrob Agents Chemother 2008; 52:3783.</a></li><li><a class="nounderline abstract_t">Costa-de-Oliveira S, Marcos Miranda I, Silva RM, et al. FKS2 mutations associated with decreased echinocandin susceptibility of Candida glabrata following anidulafungin therapy. Antimicrob Agents Chemother 2011; 55:1312.</a></li><li><a class="nounderline abstract_t">Pfeiffer CD, Garcia-Effron G, Zaas AK, et al. Breakthrough invasive candidiasis in patients on micafungin. J Clin Microbiol 2010; 48:2373.</a></li><li><a class="nounderline abstract_t">Zaoutis TE, Prasad PA, Localio AR, et al. Risk factors and predictors for candidemia in pediatric intensive care unit patients: implications for prevention. Clin Infect Dis 2010; 51:e38.</a></li><li><a class="nounderline abstract_t">Zaoutis TE, Greves HM, Lautenbach E, et al. Risk factors for disseminated candidiasis in children with candidemia. Pediatr Infect Dis J 2004; 23:635.</a></li><li><a class="nounderline abstract_t">Mermel LA, Allon M, Bouza E, et al. Clinical practice guidelines for the diagnosis and management of intravascular catheter-related infection: 2009 Update by the Infectious Diseases Society of America. Clin Infect Dis 2009; 49:1.</a></li><li><a class="nounderline abstract_t">Rex JH, Bennett JE, Sugar AM, et al. Intravascular catheter exchange and duration of candidemia. NIAID Mycoses Study Group and the Candidemia Study Group. Clin Infect Dis 1995; 21:994.</a></li><li><a class="nounderline abstract_t">Asmundsdóttir LR, Erlendsdóttir H, Gottfredsson M. Improving survival of patients with candidaemia: analysis of prognostic factors from a long-term, nationwide study in Iceland. Scand J Infect Dis 2005; 37:111.</a></li><li><a class="nounderline abstract_t">Stamos JK, Rowley AH. Candidemia in a pediatric population. Clin Infect Dis 1995; 20:571.</a></li><li><a class="nounderline abstract_t">Fisher BT, Vendetti N, Bryan M, et al. Central Venous Catheter Retention and Mortality in Children With Candidemia: A Retrospective Cohort Analysis. J Pediatric Infect Dis Soc 2016; 5:403.</a></li><li><a class="nounderline abstract_t">Buckler BS, Sams RN, Goei VL, et al. Treatment of central venous catheter fungal infection using liposomal amphotericin-B lock therapy. Pediatr Infect Dis J 2008; 27:762.</a></li><li><a class="nounderline abstract_t">Castagnola E, Marazzi MG, Tacchella A, Giacchino R. Broviac catheter-related candidemia. Pediatr Infect Dis J 2005; 24:747.</a></li><li><a class="nounderline abstract_t">Viale P, Petrosillo N, Signorini L, et al. Should lock therapy always be avoided for central venous catheter-associated fungal bloodstream infections? Clin Infect Dis 2001; 33:1947.</a></li><li><a class="nounderline abstract_t">Johnson DC, Johnson FL, Goldman S. Preliminary results treating persistent central venous catheter infections with the antibiotic lock technique in pediatric patients. Pediatr Infect Dis J 1994; 13:930.</a></li><li><a class="nounderline abstract_t">McGhee W, Michaels MG, Martin JM, et al. Antifungal Lock Therapy with Liposomal Amphotericin B: A Prospective Trial. J Pediatric Infect Dis Soc 2016; 5:80.</a></li><li><a class="nounderline abstract_t">Pieroni KP, Nespor C, Poole RL, et al. Echinocandin and ethanol lock therapy treatment of fungal catheter infections. Pediatr Infect Dis J 2013; 32:289.</a></li><li><a class="nounderline abstract_t">Baltimore RS, Gewitz M, Baddour LM, et al. Infective Endocarditis in Childhood: 2015 Update: A Scientific Statement From the American Heart Association. Circulation 2015; 132:1487.</a></li><li><a class="nounderline abstract_t">Cortegiani A, Russotto V, Maggiore A, et al. Antifungal agents for preventing fungal infections in non-neutropenic critically ill patients. Cochrane Database Syst Rev 2016; :CD004920.</a></li><li><a class="nounderline abstract_t">Blyth CC, Hale K, Palasanthiran P, et al. Antifungal therapy in infants and children with proven, probable or suspected invasive fungal infections. Cochrane Database Syst Rev 2010; :CD006343.</a></li><li><a class="nounderline abstract_t">Prasad PA, Coffin SE, Leckerman KH, et al. Pediatric antifungal utilization: new drugs, new trends. Pediatr Infect Dis J 2008; 27:1083.</a></li><li><a class="nounderline abstract_t">Palazzi DL, Arrieta A, Castagnola E, et al. Candida speciation, antifungal treatment and adverse events in pediatric invasive candidiasis: results from 441 infections in a prospective, multi-national study. Pediatr Infect Dis J 2014; 33:1294.</a></li><li><a class="nounderline abstract_t">Tsekoura M, Ioannidou M, Pana ZD, et al. Efficacy and Safety of Echinocandins for the Treatment of Invasive Candidiasis in Children: A Meta-analysis. Pediatr Infect Dis J 2019; 38:42.</a></li><li><a class="nounderline abstract_t">Walsh TJ, Whitcomb P, Piscitelli S, et al. Safety, tolerance, and pharmacokinetics of amphotericin B lipid complex in children with hepatosplenic candidiasis. Antimicrob Agents Chemother 1997; 41:1944.</a></li><li><a class="nounderline abstract_t">Schwartz GJ, Work DF. Measurement and estimation of GFR in children and adolescents. Clin J Am Soc Nephrol 2009; 4:1832.</a></li><li><a class="nounderline abstract_t">Reboli AC, Rotstein C, Pappas PG, et al. Anidulafungin versus fluconazole for invasive candidiasis. N Engl J Med 2007; 356:2472.</a></li><li><a class="nounderline abstract_t">Kuse ER, Chetchotisakd P, da Cunha CA, et al. Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trial. Lancet 2007; 369:1519.</a></li><li><a class="nounderline abstract_t">Mora-Duarte J, Betts R, Rotstein C, et al. Comparison of caspofungin and amphotericin B for invasive candidiasis. N Engl J Med 2002; 347:2020.</a></li><li><a class="nounderline abstract_t">Pappas PG, Rotstein CM, Betts RF, et al. Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis. Clin Infect Dis 2007; 45:883.</a></li><li><a class="nounderline abstract_t">Seibel NL, Schwartz C, Arrieta A, et al. Safety, tolerability, and pharmacokinetics of Micafungin (FK463) in febrile neutropenic pediatric patients. Antimicrob Agents Chemother 2005; 49:3317.</a></li><li><a class="nounderline abstract_t">Heresi GP, Gerstmann DR, Reed MD, et al. The pharmacokinetics and safety of micafungin, a novel echinocandin, in premature infants. Pediatr Infect Dis J 2006; 25:1110.</a></li><li><a class="nounderline abstract_t">Queiroz-Telles F, Berezin E, Leverger G, et al. Micafungin versus liposomal amphotericin B for pediatric patients with invasive candidiasis: substudy of a randomized double-blind trial. Pediatr Infect Dis J 2008; 27:820.</a></li><li><a class="nounderline abstract_t">Cohen-Wolkowiez M, Moran C, Benjamin DK Jr, Smith PB. Pediatric antifungal agents. Curr Opin Infect Dis 2009; 22:553.</a></li><li><a class="nounderline abstract_t">Undre NA, Stevenson P, Freire A, Arrieta A. Pharmacokinetics of micafungin in pediatric patients with invasive candidiasis and candidemia. Pediatr Infect Dis J 2012; 31:630.</a></li><li><a class="nounderline abstract_t">Benjamin DK Jr, Deville JG, Azie N, et al. Safety and pharmacokinetic profiles of repeated-dose micafungin in children and adolescents treated for invasive candidiasis. Pediatr Infect Dis J 2013; 32:e419.</a></li><li><a class="nounderline abstract_t">Steinbach WJ, Benjamin DK. New antifungal agents under development in children and neonates. Curr Opin Infect Dis 2005; 18:484.</a></li><li><a class="nounderline abstract_t">Fisher BT, Zaoutis T. Caspofungin for the treatment of pediatric fungal infections. Pediatr Infect Dis J 2008; 27:1099.</a></li><li class="breakAll">Mycamine (micafungin sodium) injection. US Food &amp; Drug Administration (FDA) approved product information. Revised December, 2019. (Available online: http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm (Accessed on January 06, 2020).</li><li><a class="nounderline abstract_t">Benjamin DK Jr, Smith PB, Arrieta A, et al. Safety and pharmacokinetics of repeat-dose micafungin in young infants. Clin Pharmacol Ther 2010; 87:93.</a></li><li><a class="nounderline abstract_t">Hope WW, Smith PB, Arrieta A, et al. Population pharmacokinetics of micafungin in neonates and young infants. Antimicrob Agents Chemother 2010; 54:2633.</a></li><li class="breakAll">Eraxis (anidulafungin). United States Prescribing Information. Revised September, 2020. US Food &amp; Drug Administration. Available online: http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm (Accessed on September 28, 2020).</li><li><a class="nounderline abstract_t">Orozco AS, Higginbotham LM, Hitchcock CA, et al. Mechanism of fluconazole resistance in Candida krusei. Antimicrob Agents Chemother 1998; 42:2645.</a></li><li><a class="nounderline abstract_t">Lee JW, Seibel NL, Amantea M, et al. Safety and pharmacokinetics of fluconazole in children with neoplastic diseases. J Pediatr 1992; 120:987.</a></li><li><a class="nounderline abstract_t">Seay RE, Larson TA, Toscano JP, et al. Pharmacokinetics of fluconazole in immune-compromised children with leukemia or other hematologic diseases. Pharmacotherapy 1995; 15:52.</a></li><li><a class="nounderline abstract_t">Walsh TJ, Karlsson MO, Driscoll T, et al. Pharmacokinetics and safety of intravenous voriconazole in children after single- or multiple-dose administration. Antimicrob Agents Chemother 2004; 48:2166.</a></li><li><a class="nounderline abstract_t">Karlsson MO, Lutsar I, Milligan PA. Population pharmacokinetic analysis of voriconazole plasma concentration data from pediatric studies. Antimicrob Agents Chemother 2009; 53:935.</a></li><li><a class="nounderline abstract_t">Brüggemann RJ, van der Linden JW, Verweij PE, et al. Impact of therapeutic drug monitoring of voriconazole in a pediatric population. Pediatr Infect Dis J 2011; 30:533.</a></li><li><a class="nounderline abstract_t">Pascual A, Calandra T, Bolay S, et al. Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes. Clin Infect Dis 2008; 46:201.</a></li><li><a class="nounderline abstract_t">Smith J, Safdar N, Knasinski V, et al. Voriconazole therapeutic drug monitoring. Antimicrob Agents Chemother 2006; 50:1570.</a></li><li><a class="nounderline abstract_t">Neely M, Rushing T, Kovacs A, et al. Voriconazole pharmacokinetics and pharmacodynamics in children. Clin Infect Dis 2010; 50:27.</a></li><li><a class="nounderline abstract_t">Doby EH, Benjamin DK Jr, Blaschke AJ, et al. Therapeutic monitoring of voriconazole in children less than three years of age: a case report and summary of voriconazole concentrations for ten children. Pediatr Infect Dis J 2012; 31:632.</a></li><li><a class="nounderline abstract_t">Pieper S, Kolve H, Gumbinger HG, et al. Monitoring of voriconazole plasma concentrations in immunocompromised paediatric patients. J Antimicrob Chemother 2012; 67:2717.</a></li><li><a class="nounderline abstract_t">Yan SQ, Seyboth B, Kobos R, et al. Voriconazole Dosing in Children Younger Than 3 Years Undergoing Cancer Chemotherapy or Hematopoietic Stem Cell Transplantation. J Pediatric Infect Dis Soc 2018; 7:169.</a></li><li><a class="nounderline abstract_t">Fraser VJ, Jones M, Dunkel J, et al. Candidemia in a tertiary care hospital: epidemiology, risk factors, and predictors of mortality. Clin Infect Dis 1992; 15:414.</a></li><li><a class="nounderline abstract_t">Andes DR, Safdar N, Baddley JW, et al. Impact of treatment strategy on outcomes in patients with candidemia and other forms of invasive candidiasis: a patient-level quantitative review of randomized trials. Clin Infect Dis 2012; 54:1110.</a></li><li><a class="nounderline abstract_t">Clancy CJ, Nguyen MH. The end of an era in defining the optimal treatment of invasive candidiasis. Clin Infect Dis 2012; 54:1123.</a></li><li><a class="nounderline abstract_t">Dutta A, Zaoutis TE, Palazzi DL. An update on the epidemiology of candidemia in children. Curr Fungal Infect Rep 2012; 6:296.</a></li><li><a class="nounderline abstract_t">Labelle AJ, Micek ST, Roubinian N, Kollef MH. Treatment-related risk factors for hospital mortality in Candida bloodstream infections. Crit Care Med 2008; 36:2967.</a></li><li><a class="nounderline abstract_t">Pappas PG, Rex JH, Lee J, et al. A prospective observational study of candidemia: epidemiology, therapy, and influences on mortality in hospitalized adult and pediatric patients. Clin Infect Dis 2003; 37:634.</a></li></ol></div><div id="topicVersionRevision">Topic 6014 Version 29.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23315320" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Finding the "missing 50%" of invasive candidiasis: how nonculture diagnostics will improve understanding of disease spectrum and transform patient care.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16758414" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Time to initiation of fluconazole therapy impacts mortality in patients with candidemia: a multi-institutional study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16127033" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Delaying the empiric treatment of candida bloodstream infection until positive blood culture results are obtained: a potential risk factor for hospital mortality.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22423135" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Septic shock attributed to Candida infection: importance of empiric therapy and source control.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17403849" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Antifungal therapy in children with invasive fungal infections: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15925667" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Antifungal agents in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23137136" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : ESCMID* guideline for the diagnosis and management of Candida diseases 2012: prevention and management of invasive infections in neonates and children caused by Candida spp.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26679628" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7935701" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. Candidemia Study Group and the National Institute.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9228472" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Multicenter randomized trial of fluconazole versus amphotericin B for treatment of candidemia in non-neutropenic patients. Canadian Candidemia Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9007589" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : A randomized study comparing fluconazole with amphotericin B/5-flucytosine for the treatment of systemic Candida infections in intensive care patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8922787" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Management of invasive candidal infections: results of a prospective, randomized, multicenter study of fluconazole versus amphotericin B and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11759644" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Fluconazole prophylaxis against fungal colonization and infection in preterm infants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8070445" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Efficacy and safety of fluconazole in the treatment of systemic fungal infections in pediatric patients. Multicentre Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10806122" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Treatment of candidal infections with fluconazole in neonates and infants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19779392" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Safety experience with caspofungin in pediatric patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16436720" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Safety and pharmacokinetics of intravenous anidulafungin in children with neutropenia at high risk for invasive fungal infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19255017" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : A prospective, multicenter study of caspofungin for the treatment of documented Candida or Aspergillus infections in pediatric patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20431381" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : A randomized, double-blind, multicenter study of caspofungin versus liposomal amphotericin B for empiric antifungal therapy in pediatric patients with persistent fever and neutropenia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21378595" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Safety of micafungin in pediatric clinical trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24892849" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Micafungin in premature and non-premature infants: a systematic review of 9 clinical trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32032174" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Safety, Efficacy and Pharmacokinetics of Anidulafungin in Patients 1 Month to&lt;2 Years of Age With Invasive Candidiasis, Including Candidemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34374424" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Comparative Effectiveness of Echinocandins vs Triazoles or Amphotericin B Formulations as Initial Directed Therapy for Invasive Candidiasis in Children and Adolescents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22278842" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Frequency of decreased susceptibility and resistance to echinocandins among fluconazole-resistant bloodstream isolates of Candida glabrata.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18676885" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Development of caspofungin resistance following prolonged therapy for invasive candidiasis secondary to Candida glabrata infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21149621" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : FKS2 mutations associated with decreased echinocandin susceptibility of Candida glabrata following anidulafungin therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20421445" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Breakthrough invasive candidiasis in patients on micafungin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20636126" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Risk factors and predictors for candidemia in pediatric intensive care unit patients: implications for prevention.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15247602" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Risk factors for disseminated candidiasis in children with candidemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19489710" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Clinical practice guidelines for the diagnosis and management of intravascular catheter-related infection: 2009 Update by the Infectious Diseases Society of America.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8645855" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Intravascular catheter exchange and duration of candidemia. NIAID Mycoses Study Group and the Candidemia Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15764202" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Improving survival of patients with candidaemia: analysis of prognostic factors from a long-term, nationwide study in Iceland.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7756477" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Candidemia in a pediatric population.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26407279" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Central Venous Catheter Retention and Mortality in Children With Candidemia: A Retrospective Cohort Analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18664989" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Treatment of central venous catheter fungal infection using liposomal amphotericin-B lock therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16094241" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Broviac catheter-related candidemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11692310" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Should lock therapy always be avoided for central venous catheter-associated fungal bloodstream infections?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7854895" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Preliminary results treating persistent central venous catheter infections with the antibiotic lock technique in pediatric patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26908494" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Antifungal Lock Therapy with Liposomal Amphotericin B: A Prospective Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23076381" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Echinocandin and ethanol lock therapy treatment of fungal catheter infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26373317" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Infective Endocarditis in Childhood: 2015 Update: A Scientific Statement From the American Heart Association.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26772902" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Antifungal agents for preventing fungal infections in non-neutropenic critically ill patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20166083" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Antifungal therapy in infants and children with proven, probable or suspected invasive fungal infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18989239" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Pediatric antifungal utilization: new drugs, new trends.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24892850" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Candida speciation, antifungal treatment and adverse events in pediatric invasive candidiasis: results from 441 infections in a prospective, multi-national study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29596219" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Efficacy and Safety of Echinocandins for the Treatment of Invasive Candidiasis in Children: A Meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9303390" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Safety, tolerance, and pharmacokinetics of amphotericin B lipid complex in children with hepatosplenic candidiasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19820136" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Measurement and estimation of GFR in children and adolescents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17568028" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Anidulafungin versus fluconazole for invasive candidiasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17482982" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12490683" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Comparison of caspofungin and amphotericin B for invasive candidiasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17806055" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16048942" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Safety, tolerability, and pharmacokinetics of Micafungin (FK463) in febrile neutropenic pediatric patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17133155" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : The pharmacokinetics and safety of micafungin, a novel echinocandin, in premature infants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18679151" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Micafungin versus liposomal amphotericin B for pediatric patients with invasive candidiasis: substudy of a randomized double-blind trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19741525" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Pediatric antifungal agents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22301478" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Pharmacokinetics of micafungin in pediatric patients with invasive candidiasis and candidemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23958810" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Safety and pharmacokinetic profiles of repeated-dose micafungin in children and adolescents treated for invasive candidiasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16258320" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : New antifungal agents under development in children and neonates.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19057369" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Caspofungin for the treatment of pediatric fungal infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19057369" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Caspofungin for the treatment of pediatric fungal infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19890251" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Safety and pharmacokinetics of repeat-dose micafungin in young infants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20308367" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Population pharmacokinetics of micafungin in neonates and young infants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20308367" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Population pharmacokinetics of micafungin in neonates and young infants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9756770" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Mechanism of fluconazole resistance in Candida krusei.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1593362" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Safety and pharmacokinetics of fluconazole in children with neoplastic diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7739946" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Pharmacokinetics of fluconazole in immune-compromised children with leukemia or other hematologic diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15155217" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Pharmacokinetics and safety of intravenous voriconazole in children after single- or multiple-dose administration.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19075073" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Population pharmacokinetic analysis of voriconazole plasma concentration data from pediatric studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21127454" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Impact of therapeutic drug monitoring of voriconazole in a pediatric population.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18171251" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16569888" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Voriconazole therapeutic drug monitoring.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19951112" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Voriconazole pharmacokinetics and pharmacodynamics in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22301479" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Therapeutic monitoring of voriconazole in children less than three years of age: a case report and summary of voriconazole concentrations for ten children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22796890" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Monitoring of voriconazole plasma concentrations in immunocompromised paediatric patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28407118" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Voriconazole Dosing in Children Younger Than 3 Years Undergoing Cancer Chemotherapy or Hematopoietic Stem Cell Transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1520786" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Candidemia in a tertiary care hospital: epidemiology, risk factors, and predictors of mortality.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22412055" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Impact of treatment strategy on outcomes in patients with candidemia and other forms of invasive candidiasis: a patient-level quantitative review of randomized trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22412062" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : The end of an era in defining the optimal treatment of invasive candidiasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : An update on the epidemiology of candidemia in children</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18824910" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Treatment-related risk factors for hospital mortality in Candida bloodstream infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12942393" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : A prospective observational study of candidemia: epidemiology, therapy, and influences on mortality in hospitalized adult and pediatric patients.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
